Anti-ICOS Monoclonal Antibody for Peripheral T-cell Lymphoma

Recruiting at 22 trial locations

Overseen by Julio C Chavez

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: National Cancer Institute (NCI)

No Placebo Group

Trial Summary

What is the purpose of this trial?

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Research Team

Julio C Chavez

Principal Investigator

University Health Network Princess Margaret Cancer Center LAO

Eligibility Criteria

This trial is for patients with certain types of T-cell lymphoma that have not improved or returned after treatment. Eligible participants must have a specific diagnosis, acceptable organ function tests, measurable disease, and an ECOG performance status of 2 or less. They should not be pregnant or breastfeeding and must agree to use contraception. People with severe allergies to similar drugs, active infections like tuberculosis, recent major surgery, uncontrolled illnesses, HIV infection or those who've had certain vaccines recently cannot join.

Inclusion Criteria

- The effects of MEDI-570 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for 3 months after the last dose of the drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must have either had a prior vasectomy or agree to use effective contraception prior to the study, during the study, and for 3 months after the last dose of the drug; males should avoid fathering children during and for at least three months after therapy is completed

For dose expansion/dose confirmation phase:

My condition worsened or didn't improve after a stem cell transplant.

Exclusion Criteria

My condition is listed as eligible for the trial.

If you have asthma or mild seasonal allergies that are well-controlled, you can still participate.

I haven't had serious infections like TB or severe herpes in the last 6 months.

Treatment Details

Interventions

• MEDI-570 (Monoclonal Antibodies)

Trial Overview The trial is testing the safety and optimal dosage of MEDI-570 in patients with relapsed/refractory peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma. MEDI-570 is a monoclonal antibody designed to modify the immune system's response and potentially inhibit tumor growth.

Participant Groups

Group I: Treatment (MEDI-570) Experimental Treatment 3 Interventions

Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School